Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02658890 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 627
- Enrollment target
NCT02658890: Completed Phase 1 study, sponsored by Bristol-Myers Squibb.
NCT02658890 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 627 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (945% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02658890, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 627 participants
- Enrollment target
Study Summary
The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 when combined with Nivolumab and in combination with Nivolumab and Ipilimumab in this patient population will also be assessed.
Primary Outcome
Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation and deaths.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 627 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 1 |
What the finished NCT02658890 record still lists
NCT02658890 is an interventional study that assigns participants to a tested intervention. The registered 627 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (945% higher).
The record links to 0 conditions, and to 3 interventions - of which Nivolumab is the first listed.
NCT02658890 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02658890 about?
NCT02658890 is a clinical study titled "An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread". The purpose of the study is to determine safety and effectiveness of experimental medication BMS-986205 when combined with Nivolumab and in combination with both Nivolumab and Ipilimumab in patients with cancers that are advanced or have spread. Pharmacokinetics and pharmacodynamics of BMS-986205 wh...
What is the current status of trial NCT02658890?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 627 participants. The study started on 2016-04-14. Estimated completion is 2021-10-26.
What interventions are being tested in trial NCT02658890?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT02658890?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02658890's enrollment target sits among peer trials
627 23rd of 2000 higher than 1,978 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06040827 · 626 participants
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI